Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
108.3 USD | -1.56% |
|
+1.10% | +72.88% |
06-27 | Natera Launches Phase 2 Gastroesophageal Cancer Trial Using Signatera | MT |
06-27 | Natera, Inc. Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.88% | 13.3B | |
+18.69% | 84.15B | |
-25.20% | 74.14B | |
+1.06% | 26.92B | |
-10.46% | 17.15B | |
-0.68% | 16.83B | |
-0.73% | 15.21B | |
+76.04% | 12.99B | |
-25.79% | 12.79B | |
+21.31% | 12.38B |
- Stock Market
- Equities
- NTRA Stock
- News Natera, Inc.
- Natera Insider Sold Shares Worth $964,194, According to a Recent SEC Filing